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To the Editor—Leonard Krilov and colleagues present their study
“Prevalence of Respiratory Syncytial Virus (RSV) Risk Factors
and Cost Implications of Immunoprophylaxis to Infants 32 to 35
Weeks Gestation for Health Plans in the United States” in the
January 2010 issue of Value in Health [1]. We take this oppor-
tunity to express our concerns about the study’s methodology
and conclusions.
First, the authors base their palivizumab effectiveness esti-
mate of 82% relative risk reduction (table 1: 10% vs. 1.8%,
8.2% absolute risk reduction) in the study group of infants at
32–35 weeks’ gestational age (wGA) on the IMpact-RSV ran-
domized clinical trial [2]. We were unable to retrieve the quoted
RSV hospitalization rate of 10% in the non–prophylaxis group
from the reference; instead, the RCT reports a background rate
of 8.1% in premature children without bronchopulmonary dys-
plasia, resulting in an absolute risk reduction of 6.3%. The
assumed background rate also exceeds the 7–8% estimate for
premature infants with multiple risk factors based on a subgroup
analysis of IMpact-RSV presented in the introduction in Krilov’s
article. In addition, contrary to the RCT, the study at hand
included children born during the RSV season. To account for the
resulting shorter exposure to the virus, the authors calculated
only 3.75 doses per child compared with 5 doses in the RCT.
Unfortunately, the authors failed to adjust the background RSV
incidence rate to reﬂect a shorter season. Evidence supporting the
need for fewer doses to achieve the same beneﬁt would be readily
embraced by third-party payers, but until this evidence becomes
available, we have to assume that this study underestimated cost
of prophylaxis by 25% and used an unsubstantiated, high back-
ground infection rate and palivizumab effectiveness estimate.
Second, the authors limit the presentation of their budget
impact analysis to cost but omit to quantify clinical beneﬁt in
their discussion section. For a hypothetical 1 million member
health plan, the study estimates incremental cost of $1129 332 to
extend prophylaxis to 419 children with any one of three risk
factors. Applying the authors’ incidence and effectiveness esti-
mates, 10% of these children would be hospitalized for RSV
infections (n = 42) and 82% (n = 34) of these hospitalizations
could be prevented with palivizumab. Following our argumen-
tation in the ﬁrst part, total cost is likely underestimated, and the
number of prevented hospitalizations most likely does not even
reach 34 in this population. Although RSV-related hospitaliza-
tions are signiﬁcant for affected families, payers need to consider
that funds allocated to prophylaxis for this small population are
not available for other, more beneﬁcial uses, including smoking
cessation programs for parents of infants, to achieve the same
goal of reducing risk for RSV infections.
Third, we question the appropriateness of a budget impact
analyses in the absence of clearly established and accepted cost-
effectiveness, because even a very costly drug with no clinical
beneﬁt would show an acceptable budget impact when given to
a small population. Krilov et al. quote a number of economic
studies sponsored by the manufacturer of palivizumab showing
cost-effectiveness estimates in support of palivizumab prophy-
laxis; however, these studies depend on the assumption that
palivizumab reduces recurrent wheezing after RSV infections.
This assumption is based on observational evidence that lacks
proper adjustment for baseline risk, and is contradicted by two
recent studies: one found that RSV infections increased the inci-
dence of asthma up to eightfold only during the ﬁrst 2 months
after RSV hospitalization, without an increased risk 1 year after
the infection [3], while a second study concluded that RSV infec-
tions can indicate a genetic predisposition but are not a cause of
asthma [4]. Without the inclusion of these long-term beneﬁts,
Elhassan et al. have shown that prophylaxis is not cost-effective
at a $200,000/QALY threshold for premature infants even at
26–32 wGA [5].
Finally, Krilov et al. state that the group of infants 32 to 35
wGA is “not a large group compared to total insured lives,” and
that per member per month cost associated with the introduction
of the 3 risk factors amounts to “only” $0.09 or 0.1% increase in
child health insurance cost. In the current health-care environ-
ment, the addition of every dollar to the nation’s health-care bill
should be seen in the light of added beneﬁts, which this study fails
to provide. By stating that inclusion of the studied risk factors as
indications for prophylaxis would only increase the nations’
health-care bill by 0.01%, the authors inappropriately downplay
the added burden to society of $231 million annually.—Christian
Hampp, PhD, and Teresa L. Kauf PhD, Pharmaceutical Outcomes
and Policy, College of Pharmacy, University of Florida, Gaines-
ville, FL, USA; and Almut G. Winterstein, PhD, Pharmaceutical
Outcomes and Policy, College of Pharmacy, and Epidemiology
and Biostatistics, College of PublicHealth andHealth Professions,
University of Florida, Gainesville, FL, USA.
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